Panelists:

Originally Aired: October 17, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

A deeper understanding of biopharmaceutical development and manufacturing processes is essential for helping scientists get the highest yield and best quality protein for their products. With this knowledge, process engineers can develop and implement protocols that reduce the potential for batch failure or manufacturing delays and eliminate human errors. Automated solutions can help engineers simplify and accelerate the development of more robust processes that get real results.

In this GEN webinar, Dr. Magnus Wetterhall will describe the automation of routine product quality and cell culture media analysis including sample preparation and data transfer for more robust results in biopharmaceutical development. He will present Waters’ bioprocess walk-up solutions, which simplify operations from sample to results even for users with little experience of LC-MS analytics. These tools are designed to help scientists automate the cell culture media measurements and capture data on product quality on upstream processes.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.

Panelists:

Originally aired: October 5, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

The scientific landscape has changed dramatically over the last ten years. Scientists have to contend with large, complex data sets, compressed timelines, and increased adoption of smart technologies. These days, it’s not uncommon for scientists to use more than 20 applications to do their work and for IT teams to support 100+ lab instruments. And FAIR data still feels out of reach. Biopharma companies that can implement a strong tech and digital strategy that creates connections, collaboration, and tames chaos, will be ahead of the curve in a new era defined by artificial intelligence and more complex datasets.

In this GEN webinar, Malay Gandhi, Chief Strategy Officer at Benchling, and DeAnna Zacherl, Executive Director for Research IT at Eli Lilly, will discuss hurdles that biopharma needs to overcome to deploy a solid tech strategy as well as the key technologies that companies are investing in.

 

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.

Originally Aired: September 29, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Cell and gene therapies have offered hope to patients with genetic abnormalities (e.g., rare diseases) or long-term disorders such as cancer. Innovative approaches for correcting sequences via editing or replacement at the genome level have changed the ways that genetic payloads are delivered to target tissues or organs. For gene therapies to be safe and efficacious, they must be delivered to the right cell type, evade immune responses, and correct the disorder they are designed for. To date, the most successful delivery vehicles are based on adeno-associated viruses (AAVs).

In this cell and gene therapy webinar, our distinguished speakers, Dr. Dominik Fischer and Dr. Michelle Fraser, will discuss recent advances and novel strategies for genetic modulation and payload delivery systems. In his talk, Dr. Fischer will discuss the potential and limitations of adeno-associated virus-based delivery of genetic therapies in the eye. His talk will sketch out the ideal payload and delivery system for ocular therapies and contrast them to AAVs. In her presentation, Dr. Fraser will share current and future trends in the development and use of genetic payloads. She will discuss some of the exciting advances in gene editing platforms and how these enable more complex editing tasks while reducing the risk of unintended genomic rearrangements.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelists.

Originally Aired: October 4, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Stability studies are essential for assessing a biotherapeutic’s sensitivity to factors that cause aggregation and ultimately degradation of the biologic. This can impact the biologic’s activity, efficacy, safety, and quality. Separating active pharmaceutical ingredients from other particle types in biotherapeutic formulations helps scientists understand the root causes of drug instability. But existing methods of characterizing particles are unreliable, slow, require significant sample volume, or are difficult to use across different therapeutics.

The Aura^® platform from Halo Labs is a USP 788 and 1788 compatible, low-volume, high throughput particle imaging system that addresses these problems. It rapidly sizes, counts, and characterizes non-proteins, polysorbate degradants, cellular and protein aggregates, or other types of molecules in heterogenous samples.

In this webinar, you’ll learn how Aura+ leverages innovative modern imaging and fluorescence microscopy techniques developed specifically for the life sciences to characterize protein, gene, and cell therapy products in stability studies. The presentation will also highlight key applications of the platform such as performing developability assessments for potential biologics.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.

Panelists:

Originally Aired: October 2, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Scientists gain a deeper understanding of different cancers when they analyze a range of omics data types. New tools like multiplexed imaging provide functionality for studying omics data in its tissue environment, shedding light on the complex pathways, networks, and mechanisms that cancer cells use to communicate and survive. By imaging RNA and protein data in the same tissue section, scientists can uncover meaningful insights about the spatial landscapes and crosstalk signaling networks of cancer cells, and further understand their role in modulating therapeutic outcomes.In this GEN webinar, Dr. Sammy Ferri-Borgogno, an instructor in the department of gynecologic oncology and reproductive medicine at MD Anderson Cancer Center, will discuss how a multi-omic approach to tissue imaging can reliably characterize the tumor microenvironment in ovarian cancer. She will discuss the capabilities of Imaging Mass Cytometry, which is used to generate high-dimensional spatial data from tissues at subcellular resolution, and why this technology is ideal for large studies involving many samples. During the webinar, you’ll learn:

• The importance of spatial cellular organization in the tumor microenvironment and its role in modulating clinical outcomes.
• How to apply a multi-omic analysis approach (proteomics, transcriptomics) to a tissue section to precisely identify novel therapeutic targets and reveal mechanisms of resistance to chemo- and immune- therapies.
• How leveraging higher-plexed Imaging Mass Cytometry can characterize spatially resolved mRNA (spatial transcriptomics) and protein (spatial proteomics) simultaneously.

 

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.

Originally Aired: September 26, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Join Dell Technologies for an engaging webinar and Q&A session on Driving Better Business Outcomes with a Data-Centric Approach in Pharma. 

During this session, we will delve into the world of data-driven decision-making and smart manufacturing and its impact on the pharmaceutical industry. Our expert speakers will highlight the importance of data management and leveraging data to transform your business. 

Key topics that will be covered include: 

• Understanding the power of data and how it can enable innovation in pharma
• Exploring the importance of data management, and how it can accelerate business outcomes
• Unveiling innovative strategies and technologies that can empower businesses to harness data effectively 

Whether you are a pharmaceutical executive, data analyst, or business professional in the life sciences industry, this webinar is designed to provide valuable insights and strategies for driving better business outcomes through a data-centric approach.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.

Originally Aired: September 27, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Many biotech and pharmaceutical companies focused on mRNA manufacturing experience challenges associated with their plasmid DNA (pDNA) supply, including slow or delayed production and poor or inconsistent DNA quality, impacting their ability to meet timelines.

In this webinar, presenters Benyamin Panah, PhD, RNA subject matter expert, Touchlight, and Scott Alderucci, director of process development, Curia, will address the evolving challenges of pDNA in mRNA manufacture, and discuss an alternative to pDNA—an enzymatic, antibiotic-free DNA vector called doggybone DNA (dbDNA). The webinar will outline how Touchlight and Curia are combining Touchlight’s dbDNA platform with Curia’s mRNA manufacturing capability to bring a rapid, reliable and high-quality solution to the market.

 

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.

 

Produced with support from:

Scott Alderucci
Director of Process Development
Curia

Benyamin Panah, PhD
RNA Subject Matter Expert
Touchlight